Profile

SAB BIO (SAB) is a clinical-stage biopharmaceutical company whose lead asset, SAB-142, uses a disease-modifying therapeutic approach aiming to delay the onset of and potentially prevent disease progression of type 1 diabetes (T1D).

Through developing human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, SAB looks to treat and prevent immune and autoimmune disorders, with a focus on T1D. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, SAB’s DiversitAb™ drug development production system can generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors.

Visit www.sab.bio

Key Products

SAB-142, a novel immunotherapy platform comprised of a human anti-thymocyte immunoglobulin (hIgG) intended to delay the onset or progression of type 1 diabetes.

Key Executives

• Samuel J. Reich, Chairman and CEO


• Eddie Sullivan, Ph.D., Co-Founder and President


• Christoph Bausch, Ph.D., MBA, EVP and Chief Operating Officer


• Dr. Alexandra Kropotova, MD, MBA, EVP and Chief Medical Officer


• Lucy To, Chief Finance Officer

Investors

NASDAQ: $SABS

Key Investor Partners:

• Sessa Capital


• BVF Partners


• RTW Investments


• Marshall Wace


• ATW


• T1D Fund

Competitors

• Vertex


• Provention Bio (acquired by Sanofi in 2023)


• Diamyd.

Corporate Responsibility

The chronic burden of type 1 diabetes is multifaceted, significantly affecting both physical and mental well-being. Managing symptoms and the risk of severe complications places a substantial strain on patients and caregivers. There is a clear and urgent need for treatment options that can delay the onset of type 1 diabetes or alter its disease trajectory. Efforts are focused on addressing this critical need and transforming the treatment paradigm for those affected by type 1 diabetes.